Embodiments relate to a method comprising (a) expressing a vector comprising a PSGL-1 (P-selectin glycoprotein ligand-1) or a mutant thereof in a VPC (virus producing cell)； and blocking a virus infection by inactivating an infectivity of a released virions from the VPC； or (b) expressing a glycoprotein or a mutant thereof in the VPC； blocking the virus infection by preventing binding of the released virions to a target cell； inactivating infectivity of the released virions； and targeting a viral infection. Other embodiments relate to (1) a broad-spectrum anti-viral product comprising: a vector expressing a glycoprotein or a mutant thereof in a VPC； and blocking a virus infection by inactivating infectivity of a released virion from the VPC； and (2) a vaccine comprising a viral particle is configured to a live attenuated or an inactivated or a non-infectious, wherein the viral particle are produced in a VPC.
